8月20日，万孚生物今日收盘23.16元，下跌6.61%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到28.23倍，总市值111.50亿元。 来源：金融界 最新一期业绩显示，2025年半年报，公司实现营业收入12.46亿元，同比-20.92%；净利润1.89亿元，同 比-46.82%，销售毛利率62.87%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13万孚生物28.2319.852.05111.50亿行业平均 59.3254.705.08121.09亿行业中值39.9739.752.9659.06亿1九安医疗11.6111.740.91195.93亿2英科医疗 15.3516.551.37242.47亿3山东药玻16.3716.421.88154.82亿4新华医疗16.4015.201.34105.14亿5奥美医疗 17.1116.761.7661.81亿6九强生物17.8316.582.1888.30亿7振德医疗18.0617.021.1565.55亿8康德莱 18.2418.261.5139.31亿9奥泰生物18.5219.531.5059.06亿10维力医疗18.6319 ...

财务费用同比激增387.74%至1669万元，主要因人民币对美元、欧元汇率波动导致汇兑损失增加，叠加 利息收入减少。研发投入2.06亿元，占营收16.5%，重点投向化学发光、分子诊断及AI辅助诊断领域。 分产品看，传染病检测收入3.79亿元（占比30.4%），同比下滑21.14%，主要因国内呼吸道检测需求回 落；慢病管理检测收入5.63亿元（占比45.2%），同比下降26.06%，主要因2024年28省IVD集采（覆盖 肿瘤标志物、甲状腺功能）落地，终端检测单价及销量承压；毒品检测收入1.45亿元（占比11.7%）， 增长4.26%，得益于北美电商渠道放量；优生优育检测收入1.38亿元（占比11.1%），下滑11.67%，出生 率低迷拖累市场表现。毛利率方面，传染病检测毛利率为59.73%（同比微降0.02个百分点），慢病管理 检测毛利率为72.86%（降2.00个百分点），毒品检测毛利率为55.76%（升0.11个百分点），优生优育检 测毛利率为43.95%（升0.67个百分点）。 南方财经8月20日电，万孚生物（300482.SZ）2025年半年度报告显示，公司上半年实现营业收入12.46 亿元，同比下降 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Wanfu Biological, indicating a decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1][2] - As of August 7, Wanfu Biological's stock closed at 24.43 yuan, with a rolling PE ratio of 22.09, marking a new low in 11 days, and a total market capitalization of 11.761 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 54.79, with Wanfu Biological ranking 49th among its peers [1][2] Group 2 - For the first quarter of 2025, Wanfu Biological reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company has received numerous accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" [1] - Wanfu Biological specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Guangzhou Wanfang Biological Technology Co., Ltd, particularly in the medical device industry [1][2] - As of June 24, the company's stock price closed at 21.06 yuan, with a rolling PE ratio of 19.04 times and a total market capitalization of 10.139 billion yuan [1] - The average PE ratio for the medical device industry is 49.12 times, with a median of 36.07 times, placing Wanfang Biological at the 45th position in the industry ranking [1] - The company reported a revenue of 800 million yuan for Q1 2025, reflecting a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] Group 2 - As of March 31, 2025, the number of shareholders for Wanfang Biological increased to 42,296, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business includes the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - Wanfang Biological has received numerous accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national-level "green factory" in January 2025 [1]

Core Viewpoint - The company Wanfu Biological has reported a decline in revenue and net profit for Q1 2025, while its PE ratio remains significantly lower than the industry average, indicating potential undervaluation in the context of the medical device sector [1][2]. Company Summary - Wanfu Biological's closing stock price is 21.01 yuan, down 1.22%, with a rolling PE ratio of 19.00 times and a total market capitalization of 10.115 billion yuan [1]. - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1]. - As of Q1 2025, nine institutions hold shares in Wanfu Biological, with a total of 81.10 million shares valued at 1.873 billion yuan [1]. Industry Summary - The average PE ratio for the medical device industry is 49.10 times, with a median of 36.43 times, positioning Wanfu Biological at the 46th rank within the industry [1][2]. - The company's Q1 2025 performance shows a revenue of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross margin of 66.67% [2]. - The company has received multiple accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" [1].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Guangzhou Wanfang Biological Technology Co., Ltd, indicating a decline in revenue and profit in the first quarter of 2025 compared to the previous year [1][2] - As of May 26, the company's stock closed at 20.85 yuan, down 1.18%, with a rolling PE ratio of 18.85 times and a total market capitalization of 10.038 billion yuan [1] - The average PE ratio for the medical device industry is 48.92 times, with a median of 35.68 times, positioning the company at 44th place within the industry [1][2] Group 2 - In Q1 2025, the company reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - The company has received numerous accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" in January 2025 [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Guangzhou Wanfang Biological Technology Co., Ltd. as of the first quarter of 2025, showing a decline in revenue and net profit compared to the previous year [1][2] - The company's stock closed at 21.61 yuan, with a rolling price-to-earnings (PE) ratio of 19.54 times, and a total market capitalization of 10.404 billion yuan [1] - The average PE ratio for the medical device industry is 49.40 times, with a median of 36.13 times, positioning the company at 45th place within the industry [1][2] Group 2 - For the first quarter of 2025, the company reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - As of the first quarter of 2025, nine institutions held shares in the company, with a total of 81.1 million shares valued at 1.873 billion yuan [1] - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Guangzhou Wanfang Biological Technology Co., Ltd., indicating a recent stock price increase and a low rolling PE ratio compared to the industry average [1][2] - As of May 12, the company's stock closed at 21.7 yuan, up 3.33%, with a rolling PE ratio of 19.62, marking a 24-day low, and a total market capitalization of 10.447 billion yuan [1] - The medical device industry has an average PE ratio of 49.84, with a median of 36.59, positioning Wanfang Biological at the 45th rank within the industry [1][2] Group 2 - For Q1 2025, the company reported revenue of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37%, with a gross profit margin of 66.67% [2] - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - Wanfang Biological has received numerous accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" as of January 2025 [1]